Marinomed Granted Chinese Patent for Antiviral Polymer
Marinomed Biotechnologie GmbH announced that it has been granted Chinese Patent No. CN101678040, entitled ‘Antiviral polymer’, by the Chinese patent office. The patent covers the use of a specific polymer for the prevention and treatment of rhinovirus infections.
Dr. Andreas Grassauer, CEO and co-founder of Marinomed, commented: “The national granting of this patent is an important further step in protecting Marinomed’s intellectual property and know-how around our anti-viral product portfolio based on our mavirex technology platform. Furthermore this patent contributes value in the out-licensing of our products or technology to partner companies in China.”
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
William S. Marth Appointed to AMRI's Board of Directors
Florida_Dental_Association
IXICO and PsiOxus Therapeutics win significant funding from government-backed Biomedical Catalyst
Novartis gains exclusive rights to Debio 025, an antiviral agent as potential first-in-class hepatitis C therapy - Novartis to make upfront payment to Debiopharm Group, with Debiopharm eligible for milestones and royalties on future sales
Merck & Co. Announces New Name for its Animal Health Division
PolyTherics appoints new Chairman
Germany Begins its First AIDS Vaccine Trial, Partnering with IAVI
MedImmune to Collaborate With National Institutes of Health to Develop Pandemic Influenza Vaccine
Pharmexa presents data from influenza program
Dental_public_health
